Dr Yuguang Wang, CEO of Maxinovel Pharmaceuticals, recaps his three decades of industry experience across Big Pharma, biotech and CRO organizations in China and the US, his motivation to establish Maxinovel Pharmaceuticals as a global, semi-virtual biotech, and their mission to develop a pipeline of orally-active one-pill combination of immuno-oncology (IO) therapy, targeted therapy and chemotherapy in order to better serve cancer patients.
I am at a stage where I have a different perspective, which allows me to conduct R&D in a different way - doing disruptive innovation
